Results 101 to 110 of about 19,263 (243)

Selective Depletion of Autoreactive Plasma Cells as a Novel Strategy to Treat Acetylcholine Receptor Antibody‐Positive Myasthenia Gravis

European Journal of Immunology, Volume 56, Issue 4, April 2026.
Current plasma cell–targeting therapies lack antigen specificity. Using an antibody‐mediated cytotoxicity engager (ACE) targeting the α‐subunit of the extracellular domain of the human acetylcholine receptor (hAChR αECD), we selectively depleted pathogenic antibody‐secreting cells in a myasthenia gravis model, reducing autoantibody titers and disease ...
Laleh Khodadadi, Deborah Puppe, Dilara S. Cirillo, Carolina Martinez‐Cingolani, Jens Klotsche, Andreas Pelz, Siegfried Kohler, Qingyu Cheng, Konstantinos Lazaridis, Michael Fichtner, Jan Pille, Andrey Kruglov, Marina Bondareva, Tobias Alexander, Andreas Radbruch, Andreas Meisel, Falk Hiepe   +16 more
wiley   +1 more source

Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma

BMC Cancer
Background Daratumumab is a human IgGκ monoclonal antibody targeting CD38 with direct on-tumor and immunomodulatory mechanisms of action. Daratumumab-based treatment is a standard of care for multiple myeloma (MM) based on data from randomized controlled
Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu   +17 more
doaj   +1 more source

New agents in the Treatment of Myeloma Bone Disease [PDF]

, 2017
Patients with multiple myeloma develop a devastating bone disease driven by the uncoupling of bone remodelling, excess osteoclastic bone resorption and diminished osteoblastic bone formation.
Chantry, A.D., Jolley, I., Lawson, M.A., Ring, E.S., Snowden, J.A.   +4 more
core   +2 more sources

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

DARATUMUMAB: REVISÃO DA ATUAÇÃO E INTERFERÊNCIA NOS TESTES PRÉ- TRANSFUSIONAIS EM PACIENTES COM DIAGNOSTICO DE MIELOMA MÚLTIPLO

Hematology, Transfusion and Cell Therapy
Objetivo: Discutir a interferência da medicação Daratumumab nos testes pré-transfusionais em amostras de pacientes diagnosticados com Mieloma Múltiplo que necessitam de transfusões sanguíneas.
GN Leôncio
doaj   +1 more source

Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. [PDF]

, 2019
Despite the many prospective randomized trials that have been available in the past decade regarding the optimization of radiation, hormonal, and surgical therapies for high-risk prostate cancer (PCa), many questions remain.
Chen, Victor E., Den, Robert B., Greenberger, Benjamin A.   +2 more
core   +1 more source

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study [PDF]

, 2022
Habte Yimer, Jason M. Melear, Edward A. Faber, William Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Kathleen Gray, Yana Lutska, Padma Bobba, Keqin Qi, Daniela Hoehn, Ming Qi, Thomas S. Lin, Robert M. Rifkin   +14 more
openalex   +1 more source

Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma:CASSIOPEIA minimal residual disease results [PDF]

Previous results from CASSIOPEIA demonstrated superior progression-free survival (PFS) and minimal residual disease (MRD) negativity with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (VTd) induction/consolidation and with ...
Borgsten, Fredrik, Broijl, Annemiek, Béné, Marie C., Cabarrou, Bastien, Caillot, Denis, Carson, Robin, Corre, Jill, de Boer, Carla, Dejoie, Thomas, Delforge, Michel, Facon, Thierry, Filleron, Thomas, Hebraud, Benjamin, Hua, Winnie, Hulin, Cyrille, Krevvata, Maria, Lambert, Jérôme, Leleu, Xavier, Macro, Margaret, Mahéo, Sabrina, Moreau, Philippe, Perrot, Aurore, Rowe, Melissa, Sonneveld, Pieter, Tuozzo, Alba, van de Donk, Niels W.C.J., Vanquickelberghe, Véronique, Vincent, Laure, Wang, Jianping, Wuilleme, Soraya, Zweegman, Sonja   +30 more
core   +1 more source

Daratumumab – Hope for Myeloma Patients, a Challenge for Clinical Laboratories [PDF]

, 2017
Tomáš Jelı́nek, Martin Kořístka, Zdeňka Čermáková, Roman Hájek   +3 more
openalex   +1 more source

HASH(0x563d442697c0) [PDF]

, 2016
HASH(0x563d4416ce80)HASH ...
Grössmann, N.
core